# US 2026/0055382 A1 · Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0055382 A1
- Document ID: US20260055382A1
- Status: Published application
- Kind: A1
- Application number: 19/278,336
- Filed: 2025-07-23
- Published: 2026-02-26
- Earliest claimed: 2012-03-23
- Assignees: Codexis, Inc.
- Applicants: Codexis, Inc.
- Inventors: Jovana Nazor; Derek J. Smith; Michael A. Crowe; Shiwei Song; Steven J. Collier
- Web page: https://patentgrep.com/patent/US20260055382A1

## CPC

- C12N 9/1096: {transferring nitrogenous groups (2.6)}
- C12P 17/10: Nitrogen as only ring hetero atom
- C12Y 206/01: Transaminases (2.6.1)
- C12Y 206/01018: Beta-alanine-pyruvate transaminase (2.6.1.18)
- Y02P 20/52: using catalysts, e.g. selective catalysts
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

## Claims

### Claim 1

An engineered polypeptide having transaminase activity, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 4 and one or more residue differences as compared to SEQ ID NO:4 at residue positions selected from: X14, X26, X31, X33, X41, X47, X57, X70, X86, X88, X107, X132, X148, X163, X168, X173, X203, X250, X284, X314, X315, X324, X346, X395, X398, X400, X417, X419, X423, X448, and X451, wherein the residue differences at residue positions X31, X57, X86, X163, X168, X314, X324, X398, and X417 are selected from: X31 S, X57Y, X86D, X163I, X163L, X163R, X163V, X168S, X314N, X324H, X398L, X398V, X398W, and X417M.

### Claim 2 (depends on 1)

The engineered polypeptide of claim 1, wherein the residue difference at the residue positions X14, X26, X33, X41, X47, X70, X88, X107, X132, X148, X173, X203, X250, X284, X315, X346, X395, X400, X419, X423, X448, and X451 are selected from X14V, X26R, X33T, X41L, X47N, X70A, X88A, X88L, X107P, X132F, X148Q, X148R, X173A, X203S, X250A, X284A, X315G, X346L, X395P, X400G, X419S, X423I, X448E, and X451D.

### Claim 3 (depends on 2)

The engineered polypeptide of claim 2 in which the amino acid sequence further comprises one or more residue differences selected from: X57F, X113L, X113V, X168K, X420N, and X424V.

### Claim 4 (depends on 1)

The engineered polypeptide of claim 1, wherein the amino acid sequence further comprises at least one or more residue differences selected from X14V, X26R, X31S/D, X86D, X163U/RN, X315G, X398L/V/W, and X400G.

### Claim 5 (depends on 1)

The engineered polypeptide of claim 1, wherein the amino acid sequence comprises a combination of residue differences selected from:
X14V and X163I/L/R/V,
X86D and X400G,
X57F/Y and X163I/L/R/V,
X57F/Y and X398L/V/W,
X14V, X113L/V, X163I/L/R/V, X284A, and X424V,
X31S, X57F/Y, X163I/I/R/V, X315G, X346L, and X398L/V/W
X14V, X113L, X163L, X284A, and X424V,
X14V, X26R, X163L, X284A, and X400G,
X14V, X26R, X88L, and X113L,
X57F, X163L, X168K, X314N, X315G, X346L, and X398V,
X14V, X163L, X173A, X400G, and X420N,
X14V, X113L, X163L, and X284A,
X14V, X26R, X163L, X284A, and X400G, and
X14V, X33T, X57F, X113L, and X163L.

### Claim 6 (depends on 1)

The engineered polypeptide of claim 1, wherein said polypeptide has at least 1.2 fold increased stability as compared to the polypeptide of SEQ ID NO:4.

### Claim 7 (depends on 1)

The engineered polypeptide of claim 1, wherein the amino acid sequence comprises a sequence selected from: SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, and 154.

### Claim 8 (depends on 1)

The engineered polypeptide of claim 1, wherein said polypeptide is immobilized on a solid support.

### Claim 9 (depends on 1)

A polynucleotide encoding the engineered polypeptide of claim 1.

### Claim 10 (depends on 9)

An expression vector comprising the polynucleotide of claim 9, optionally further comprising a control sequence.

### Claim 11 (depends on 9)

A host cell comprising the polynucleotide of claim 9.

### Claim 12 (depends on 10)

A host cell comprising the expression vector of claim 10.

### Claim 13 (depends on 11)

A method of preparing the engineered polypeptide comprising culturing the host cell of claim 11, under conditions suitable for expression of the polypeptide, optionally further comprising isolating the engineered polypeptide.

### Claim 14 (depends on 12)

A method of preparing the engineered polypeptide comprising culturing the host cell of claim 12, under conditions suitable for expression of the polypeptide, optionally further comprising isolating the engineered polypeptide.

### Claim 15 (depends on 1)

A process for preparing a compound of formula (I),
wherein
R1 is selected from the group consisting of hydrogen, carboxy, carboxy(C1-C6)alkyl, optionally substituted (C1-C6)alkyl, optionally substituted (C2-C6)alkenyl, optionally substituted alkyloxycarbonyl, optionally substituted arylcarbonyl, optionally substituted arylsulfonyl, and a protecting group;
R2 is selected from the group consisting of hydrogen, oxo, halo, hydroxy, amino, thio, optionally substituted (C1-C6)alkyl, (C1-C6)alkylamino, (C1-C6)dialkylamino, (C1-C6)alkylthio, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfinyl, and optionally substituted (C1-C6)alkyloxy;
R4, R6 and R7 are each, independently of the others, selected from the group consisting of hydrogen, halo, hydroxy, amino, carboxy, cyano, nitro, thio, optionally substituted (C1-C6)alkyl, hydroxy(C1-C6)alkyl, optionally substituted (C1-C6)alkyloxy, optionally substituted (C1-C6)alkylamino, optionally substituted (C1-C6)dialkylamino, optionally substituted (C1-C6)alkylthio, optionally substituted (C1-C6)alkylsulfonyl, optionally substituted (C1-C6)alkylsulfinyl, carboxy(C1-C6)alkyl, (C1-C6)alkyloxycarbonyl, (C1-C6)alkylcarbonyloxy, optionally substituted aminocarbonyl, aminocarbonyl(C1-C6)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylamino, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfinyl, optionally substituted aryloxycarbonyl, optionally substituted arylcarbonyloxy, optionally substituted heteroaryloxy, optionally substituted heteroarylamino, optionally substituted heteroarylthio, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfinyl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyloxy, alkylaminosulfonyl(C1-C6)alkyl, arylsulfonyl(C1-C6)alkyl, and heteroarylsulfonyl(C1-C6)alkyl;
R5 is selected from the group consisting of hydrogen, halo, hydroxy, amino, carboxy, cyano, nitro, thio, optionally substituted (C1-C6)alkyl, hydroxy(C1-C6)alkyl, optionally substituted (C1-C6)alkyloxy, optionally substituted (C1-C6)alkylamino, optionally substituted (C1-C6)dialkylamino, optionally substituted (C1-C6)alkylthio, optionally substituted (C1-C6)alkylsulfonyl, optionally substituted (C1-C6)alkylsulfinyl, carboxy(C1-C6)alkyl, (C1-C6)alkyloxycarbonyl, (C1-C6)alkylcarbonyloxy, optionally substituted aminocarbonyl, aminocarbonyl(C1-C6)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylamino, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfinyl, optionally substituted aryloxycarbonyl, optionally substituted arylcarbonyloxy, optionally substituted heteroaryloxy, optionally substituted heteroarylamino, optionally substituted heteroarylthio, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfinyl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyloxy, alkylaminosulfonyl(C1-C6)alkyl, arylsulfonyl(C1-C6)alkyl, and heteroarylsulfonyl(C1-C6)alkyl, or together with R4 forms a 5 to 8 membered optionally substituted cycloalkyl or optionally substituted heterocyclic ring;
R8 is selected from the group consisting of optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6)alkyloxy, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or together with R2 forms an optionally substituted 5 to 8 membered cycloalkyl or heterocyclic ring; and
n is 1 or 2;
with the provisos that
(a) when R2 is hydrogen, then at least one of the following applies:
(i) R1 is not hydrogen, methyl, 4-(methyloxy)phenylcarbonyl-, 4-(trifluoromethyloxy)phenylsulfonyl-, 3-bromophenylcarbonyl-, 3-aminopropyl-, or 3-(methylcarbonylamino)propyl-;
(ii) R4 and R7 are each, independently of the other, not hydrogen or chloro;
(iii) R5 is not hydrogen, hydroxy, methyl, methyloxy, fluoro, chloro, trifluoromethyl, or cyano;
(iv) R6 is not hydrogen, hydroxy, methyloxy, fluoro or chloro; or
(v) R8 is not methyl, ethyl, hydroxymethyl, or trifluoromethyl-; and
(b) when n is 1, R2 and R8 together form a cyclohexyl ring, and R1, R4, R6, and R7 are hydrogen, then R5 is not fluoro;
comprising contacting the substrate compound of formula (II),
wherein R1, R2, R4, R5, R6, R7, R8 and n are as defined above,
in presence of an amino donor under suitable reaction conditions with an engineered polypeptide of claim 1.

### Claim 16 (depends on 15)

The process of claim 15, wherein the compound of formula (I) comprises the compound of formula (IS),
having the indicated stereochemistry at the carbon atom marked with an *, wherein compound (IS) is formed in enantiomeric excess.

### Claim 17 (depends on 1)

A process for preparing a compound of formula (Ia):
wherein,
R1 is selected from the group consisting of hydrogen, carboxy, carboxy(C1-C6)alkyl, optionally substituted (C1-C6)alkyl, optionally substituted (C2-C6)alkenyl, optionally substituted alkyloxycarbonyl, optionally substituted arylcarbonyl, optionally substituted arylsulfonyl, and a protecting group;
R2 is selected from the group consisting of hydrogen, oxo, halo, hydroxy, amino, thio, optionally substituted (C1-C6)alkyl, (C1-C6)alkylamino, (C1-C6)dialkylamino, (C1-C6)alkylthio, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfinyl, and optionally substituted (C1-C6)alkyloxy;
R4, R5, R6 and R7 are each, independently of the others, selected from the group consisting of hydrogen, halo, hydroxy, amino, carboxy, cyano, nitro, thio, optionally substituted (C1-C6)alkyl, hydroxy(C1-C6)alkyl, optionally substituted (C1-C6)alkyloxy, optionally substituted (C1-C6)alkylamino, optionally substituted (C1-C6)dialkylamino, optionally substituted (C1-C6)alkylthio, optionally substituted (C1-C6)alkylsulfonyl, optionally substituted (C1-C6)alkylsulfinyl, carboxy(C1-C6)alkyl, (C1-C6)alkyloxycarbonyl, (C1-C6)alkylcarbonyloxy, optionally substituted aminocarbonyl, aminocarbonyl(C1-C6)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylamino, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfinyl, optionally substituted aryloxycarbonyl, optionally substituted arylcarbonyloxy, optionally substituted heteroaryloxy, optionally substituted heteroarylamino, optionally substituted heteroarylthio, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfinyl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyloxy, alkylaminosulfonyl(C1-C6)alkyl, arylsulfonyl(C1-C6)alkyl, and heteroarylsulfonyl(C1-C6)alkyl; and
R8 is selected from the group consisting of optionally substituted (C1-C6) alkyl, optionally substituted (C1-C6)alkyloxy, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
with the proviso that when R2 is hydrogen, then at least one of the following applies:
(i) R1 is not hydrogen, methyl, 4-(methyloxy)phenylcarbonyl-, 4-(trifluoromethyloxy)phenylsulfonyl-, 3-bromophenylcarbonyl-, 3-aminopropyl-, or 3-(methylcarbonylamino)propyl-;
(ii) R4 and R7 are each, independently of the other, not hydrogen or chloro;
(iii) R5 is not hydrogen, hydroxy, methyl, methyloxy, fluoro, chloro, trifluoromethyl or cyano;
(iv) R6 is not hydrogen, hydroxy, methyloxy, fluoro or chloro; or
(v) R8 is not methyl, ethyl, hydroxymethyl-, or trifluoromethyl-;
comprising contacting the substrate compound of formula (IIa)
wherein R1, R2, R4, R5, R6, R7, and R8 are as defined above,
in presence of an amino donor under suitable reaction conditions with an engineered transaminase polypeptide of claim 1.

### Claim 18 (depends on 17)

The process of claim 17, wherein the compound of formula (Ia) comprises the compound of formula (IaS)
having the indicated stereochemistry at the carbon atom marked with an *, wherein compound (IaS) is formed in enantiomeric excess.

### Claim 19 (depends on 1)

A process for preparing a compound of formula (Ia1)
wherein
R1 is selected from the group consisting of hydrogen and (C1-C6)alkyl;
R2 is selected from the group consisting of hydrogen, halo, and (C1-C6)alkyl;
R4, R5, R6, and R7 are each, independently of the others, selected from the group consisting of hydrogen, halo, hydroxy, optionally substituted (C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkyl; amino, (C1-C6)alkylamino, and (C1-C6)dialkylamino; and
R9 is selected from the group consisting of halo, hydroxy, hydroxy(C1-C6)alkyl, amino, (C1-C6)alkylamino, and (C1-C6)dialkylamino;
with the proviso that when R2 is hydrogen, then at least one of the following applies:
(i) R1 is not hydrogen or methyl;
(ii) R4 and R7 are each, independently of the other, not hydrogen or chloro;
(iii) R5 is not hydrogen, hydroxy, methyl, methyloxy, fluoro, chloro, or trifluoromethyl;
(iv) R6 is not hydrogen, hydroxy, methyloxy, fluoro or chloro; or
(v) R9 is not hydroxy;
comprising contacting the substrate compound of formula (IIa1)
wherein
R1, R2, R4, R5, R6, R7 and R9 are as defined above,
in presence of an amino donor under suitable reaction conditions with an engineered polypeptide of claim 1.

### Claim 20 (depends on 1)

A process for preparing a compound of formula (Ia2)
wherein
L is a leaving group;
each occurrence of R10 is, independently of the others, selected from the group consisting of halo, hydroxy, amino, carboxy, cyano, nitro, thio, optionally substituted (C1-C6)alkyl, hydroxy(C1-C6)alkyl, optionally substituted (C1-C6)alkyloxy, optionally substituted (C1-C6)alkylamino, optionally substituted (C1-C6)dialkylamino, optionally substituted (C1-C6)alkylthio, optionally substituted (C1-C6)alkylsulfonyl, optionally substituted (C1-C6)alkylsulfinyl, carboxy(C1-C6)alkyl, (C1-C6)alkyloxycarbonyl, (C1-C6)alkylcarbonyloxy, optionally substituted aminocarbonyl, aminocarbonyl(C1-C6)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylamino, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfinyl, optionally substituted aryloxycarbonyl, optionally substituted arylcarbonyloxy, optionally substituted heteroaryloxy, optionally substituted heteroarylamino, optionally substituted heteroarylthio, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfinyl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyloxy, alkylaminosulfonyl(C1-C6)alkyl, arylsulfonyl(C1-C6)alkyl, and heteroarylsulfonyl(C1-C6)alkyl;
k is an integer from 3 to 5;
n is 1 or 2; and
w is an integer from 0 to 4;
comprising contacting the substrate compound of formula (IIa2)
wherein
L, R10, k, n and w are as defined above;
in presence of an amino donor under suitable reaction conditions with an engineered polypeptide of claim 1.

### Claim 21 (depends on 20)

The process of claim 20, wherein L is Cl or Br and k is 3.

### Claim 22 (depends on 1)

A process for preparing a compound of formula (Ib)
wherein
Z is selected from the group consisting of O, S, NH or —(CH2)m—, wherein m is 0, 1, 2 or 3;
R1 is selected from the group consisting of hydrogen, carboxy, carboxy(C1-C6)alkyl, optionally substituted (C1-C6)alkyl, optionally substituted (C2-C6)alkenyl, optionally substituted alkyloxycarbonyl, optionally substituted arylcarbonyl, optionally substituted arylsulfonyl, and a protecting group;
R4, R5, R6 and R7 are each, independently of the others, selected from the group consisting of hydrogen, halo, hydroxy, amino, carboxy, cyano, nitro, thio, optionally substituted (C1-C6)alkyl, hydroxy(C1-C6)alkyl, optionally substituted (C1-C6)alkyloxy, optionally substituted (C1-C6)alkylamino, optionally substituted (C1-C6)dialkylamino, optionally substituted (C1-C6)alkylthio, optionally substituted (C1-C6)alkylsulfonyl, optionally substituted (C1-C6)alkylsulfinyl, carboxy(C1-C6)alkyl, (C1-C6)alkyloxycarbonyl, (C1-C6)alkylcarbonyloxy, optionally substituted aminocarbonyl, aminocarbonyl(C1-C6)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylamino, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfinyl, optionally substituted aryloxycarbonyl, optionally substituted arylcarbonyloxy, optionally substituted heteroaryloxy, optionally substituted heteroarylamino, optionally substituted heteroarylthio, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfinyl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyloxy, alkylaminosulfonyl(C1-C6)alkyl, arylsulfonyl(C1-C6)alkyl, and heteroarylsulfonyl(C1-C6)alkyl;
with the proviso that when Z is —(CH2)m—, m is 1, and R1, R4, R6 and R7 are hydrogen, then R5 is not fluoro;
comprising contacting the substrate compound of formula (fib)
wherein Z, R1, R4, R5, R6, and R7 are as defined above;
in presence of an amino donor under suitable reaction conditions with an engineered polypeptide of claim 1.

### Claim 23 (depends on 1)

A process for preparing a compound of formula (Ib1)
wherein
R1 is selected from the group consisting of hydrogen, carboxy(C1-C6)alkyl, and (C1-C6)alkyl;
each occurrence of R11 is, independently of the others, selected from the group consisting of chloro, bromo, iodo, hydroxy, amino, carboxy, cyano, nitro, thio, optionally substituted (C1-C6)alkyl, hydroxy(C1-C6)alkyl, optionally substituted (C1-C6)alkyloxy, optionally substituted (C1-C6)alkylamino, optionally substituted (C1-C6)dialkylamino, optionally substituted (C1-C6)alkylthio, optionally substituted (C1-C6)alkylsulfonyl, optionally substituted (C1-C6)alkylsulfinyl, carboxy(C1-C6)alkyl, (C1-C6)alkyloxycarbonyl, (C1-C6)alkylcarbonyloxy, optionally substituted aminocarbonyl, aminocarbonyl(C1-C6)alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted arylamino, optionally substituted arylthio, optionally substituted arylsulfonyl, optionally substituted arylsulfinyl, optionally substituted aryloxycarbonyl, optionally substituted arylcarbonyloxy, optionally substituted heteroaryloxy, optionally substituted heteroarylamino, optionally substituted heteroarylthio, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfinyl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyloxy, alkylaminosulfonyl(C1-C6)alkyl, arylsulfonyl(C1-C6)alkyl, and heteroarylsulfonyl(C1-C6)alkyl; and
w is an integer from 0 to 4;
comprising contacting the substrate compound of formula (IIb1)
wherein
R1, R11 and w are as defined above;
in presence of an amino donor under suitable reaction conditions with an engineered polypeptide of claim 1.
